Skip to content

Effects of lavender essential oil inhalation aromatherapy on anxiety and pain in advanced lang cancer patients: A parallel randomized controlled trial

Effects of lavender essential oil inhalation aromatherapy on anxiety and pain in advanced lang cancer patients: A parallel randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108838
Enrollment
Unknown
Registered
2025-09-08
Start date
2025-09-20
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Lavender essential oil group:Subjects completed 3 sniffs (Lavandula angustifolia,0.5%) in the morning upon awakening and in the evening before going to bed for 5 consecutive days of the intervention.
Normal saline group:Subjects completed 3 sniffs (NaCl,0.9%) in the morning upon awakening and in the evening before going to bed for 5 consecutive days of the intervention.

Sponsors

Shanxi Bethune Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age18-65 years; 2. No communication disorders and consent to participate in the study; 3.Histopathologically confirmed diagnosis of lung cancer; 4. Tumor stage IIIB or IIIC or IVA; 5.Hospitalization in the Department of Thoracic Oncology for at least 7 consecutive days.

Exclusion criteria

Exclusion criteria: 1. Previous radical surgery for lung cancer; 2. Current use of other non-pharmacological therapies (aromatherapy, analgesic herbs, listening to music, massage); 3. Allergy to any essential oils; 4. Patient self-reported severe olfactory disturbances; 5. Comorbid known psychiatric disorders (anxiety disorders, panic disorders, depressions); 6.Comorbid serious dysfunction of cardiovascular, hepatic, renal, and other vital organs; 7.Disease that has progressed to end-stage with an expected survival of less than 6 months; 8. Participation in another clinical study within three months.

Design outcomes

Primary

MeasureTime frame
Spielberger’s State-Trait Anxiety Inventory,STAI;

Secondary

MeasureTime frame
Numerical Rating Scale,NRS;Pittsburgh Sleep Quality Index,PSQI;Piper Fatigue Scale,PFS;

Countries

China

Contacts

Public ContactYuan Ting

Shanxi Bethune Hospital

yuan199012180504@163.com+86 151 3514 1643

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026